Saudi Arabia’s General Authority for Military Industries Announces a Fully Integrated Defense Show Starting March 2022
17.7.2020 00:05:00 EEST | Business Wire | Press release
Today the Kingdom of Saudi Arabia’s General Authority for Military Industries (GAMI) announced the launch of ‘World Defense Show’. The show will take center stage in the global defense show circuit, offering exhibitors and visitors the opportunity to participate in Saudi Arabia’s first truly integrated defense show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716006046/en/
His Excellency Ahmad Al Ohali, Governor of GAMI (Photo: AETOSWire)
Founded by GAMI, World Defense Show is focused on interoperability across air, land, sea, security innovative defense technologies and satellite defense systems. The inaugural event is scheduled to take place between 6th and 9th March 2022 and will then be held biennially in Saudi Arabia’s capital, Riyadh.
Speaking at a virtual press conference attended by international defense companies, GAMI’s Governor, His Excellency Ahmad Al Ohali stated: “As Technology is accelerating the rate at which the global defense industry is evolving, defense considerations are becoming increasingly complex. There is a need for a platform, which enables the defense community to convene and collectively consider the great opportunities and challenges that are facing us all. This is why we are launching World Defense Show, an innovative platform showcasing, through both live and virtual demonstrations, the possibilities that interoperability can provide across all five defense domains: Air, Land, Sea, Security and Satellite.”
He added, “There is no better place than Saudi Arabia to organize a defense event at this scale. A G20 country, the Kingdom is one of the world’s biggest defense spenders with a strategic location at the center of three continents, making it an ideal hub for defense trade and innovation. Saudi Arabia’s vision to localize 50% of its multi-billion-dollar defense expenditure by 2030 also presents massive opportunities to global industry OEMs and investors.”
GAMI has recruited a team of international experts to organize and run event operations.
Shaun Ormrod, Chief Executive Officer, World Defense Show, said: “Today’s launch of World Defense Show marks an exciting inflection point for the defense industry and a step forward in the ambition and scale of a defense trade show. Through World Defense Show we will demonstrate why Saudi Arabia is critical to the defense industry’s future. The platform will enable access to dedicated programs that support Saudi Arabia’s local businesses, it will leverage investment opportunities and encourage a new generation to aspire to work in the defense industry.” Mr. Ormrod is the former CEO of Farnborough Airshow with over 20 years of industry trade show expertise.
Over four days, World Defense Show will showcase comprehensive and interactive displays of integrated defense technology solutions, alongside conferences and thought leadership seminars focused on the next generation of defense. The show’s venue, estimated to accommodate 80,000 square meters of exhibition, hospitality and outdoor area, will feature demonstration facilities and virtual technological capabilities to showcase every defense domain on an unprecedented scale.
Video News Release embed and download link here
About World Defense Show
World Defense Show is a display and demonstration of integrated and innovation-driven defense solutions, set to serve as the global stage for defense interoperability. The inaugural World Defense Show will take place biannually starting March 2022 in Riyadh - Saudi Arabia, to showcase the latest in interoperable defense solutions. The event will be held in the presence of Saudi Arabia’s key leadership, international delegations and prominent industry decision makers from around the world.
About General Authority for Military Industries
The founder of World Defense Show, Saudi Arabia’s General Authority for Military Industries, is the regulator, enabler and licensor for the kingdom’s military industry. GAMI is responsible for domestic defense sector development in line with the national commitment to localize 50% of military manufacturing by 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716006046/en/
Contact information
Yara Abifaker, +971544285342
yara.abifaker@finsbury.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom